Where is Incyte Corporation (INCY) Headed According to Analysts?

Incyte Corporation (NASDAQ:INCY) is one of the best immunotherapy stocks to buy according to hedge funds. Jefferies reiterated a Buy rating on Incyte Corporation (NASDAQ:INCY) on February 11, setting a price target of $120. The same day, Morgan Stanley also lifted the price target on the stock to $102 from $94 while maintaining an Equal Weight rating on the shares.

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds is Buying

Incyte Corporation also received a bullish rating update from Stifel on February 11, with the firm raising the price target on the stock to $120 from $119 while maintaining a Buy rating and noting that it anticipates a “quiet(ish)” first half. However, it still likes the longer-term, ex-Jakafi foundation.

The bullish rating updates came after Incyte Corporation announced financial results for fiscal Q4 and the full year ended December 31, 2025, on February 10, reporting a total revenue of $1.51 billion for the quarter, up 28% compared to the prior year period. Management attributed the growth to an increase in total net product revenue and milestone and contract revenue. Total revenue for the full year reached $5.14 billion, reflecting a growth of 21% compared to the prior year period and primarily driven by growth in the total net product revenue and milestone and contract revenue.

Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics, focusing on oncology, hematology, inflammation, and autoimmunity therapeutic areas.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.